Columbia University Medical Center to evaluate Biocept's Target Selector platform to

[News]

Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that Columbia University Medical Center will conduct a study to evaluate the clinical utility of the Company's Target Selector™ platform to diagnose leptomeningeal metastases (LM) in patients with breast cancer.

More... (http://www.news-medical.net/news/20161230/Columbia-University-Medical-Center-to-evaluate-Biocepts-Target-Selector-platform-to-diagnose-LM-in-breast-cancer-patients.aspx)